Biopharma Co. Accused Of Lying To Investors About FDA Hold
An investor in biotherapeutics company Kiromic BioPharma Inc. has launched a proposed class action accusing the company and its leadership of touting prospects for two drug candidates ahead of a 2021...To view the full article, register now.
Already a subscriber? Click here to view full article